Developing Ex Vivo Models in Breast and Lung Cancers
This infrastructure award is focusing on developing our ability to develop human-derived models representing at risk normal tissue or early malignant lesions for study cancers such as breast and lung cancer. These models will explore the process of cancer initiation and open up new mechanisms for identifying the earliest stages of cancer transformation and biomarkers. This capacity once tested will provide a testbed with which can be used for research models of other cancers ex vivo.
About ACED Manchester
ACED is a £55 million partnership between world-leading early detection institutes and organisations dedicated to improving the early detection of cancer.